Skip to content

Clinical Efficacy Evaluation and Central Mechanism Research of Acupuncture Treatment for Post-stroke Vascular Vertigo

Clinical Efficacy Evaluation and Central Mechanism Research of Acupuncture Treatment for Post-stroke Vascular Vertigo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001283
Enrollment
Unknown
Registered
2025-06-27
Start date
2025-06-28
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post - stroke vascular vertigo

Interventions

Acupuncture Group:Acupuncture
Sham Acupuncture Group:Sham Acupuncture
Drug Control Group:Oral administration of Betahistine Mesilate Tablets

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu City Sichuan Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meeting the above - mentioned diagnostic criteria for post - stroke vascular vertigo; (2) Gender is not limited and the age is between 30 and 80 years old (inclusive); (3) The onset of cerebral infarction or cerebral hemorrhage is more than 2 weeks ago and symptoms such as vertigo dizziness or instability persist for = 1 week; (4) The occurrence of vertigo - related symptoms is not earlier than the onset and diagnosis time of cerebral infarction or cerebral hemorrhage; (5) The score of the Barthel Index Rating Scale is > 40 points; (6) Those with stable vital signs and basic condition; (7) Being able to complete the vertigo diary; (8) The subject himself/herself signs or a direct relative signs the informed consent form on behalf of the subject and volunteers to participate in this study. Note: Only subjects who meet all of the above 8 items can be included in this study.

Exclusion criteria

Exclusion criteria: (1) Those whose vertigo is confirmed by examination to be caused by other diseases and trauma such as vertigo caused by intracranial space - occupying lesions otogenic metabolic infectious diseases etc.; (2) Vascular vertigo excluding vertebral artery compression syndrome (vertigo induced by head movement caused by sustained eccentric neck postures etc.; nystagmus occurs during the attack); (3) Patients with severe primary diseases of the cardiovascular liver kidney digestive hematopoietic systems etc.; (4) Those who have had other central nervous system disorders (such as Parkinson's disease intracranial infection etc.) in the past six months; (5) Those with severe skin damage or skin diseases at the treatment site; (6) Patients with coagulation disorders or hemorrhagic diseases; (7) Pregnant women lactating women and women who plan to have children in the next six months; (8) Those who cannot understand or record the vertigo diary; (9) Comatose patients and those with impaired consciousness; (10) People who cannot complete the study due to mental illness cognitive or emotional disorders; (11) Those who are currently participating or have participated in other clinical trials in the past three months. Note: Any subject who meets any of the above criteria should be excluded.

Design outcomes

Primary

MeasureTime frame
dizziness handicap inventory;

Secondary

MeasureTime frame
Functional Magnetic Resonance Imaging (fMRI) Detection;Dizziness and Anxiety Rating Scale;health survey short form 36 questionaire;Vertigo Diary;Transcranial Doppler Ultrasound(Cerebral Blood Flow Monitoring Indicators);

Countries

China

Contacts

Public ContactSong Jin

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

1049147000@qq.com18980880353

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 26, 2026